Biosynex (ALBIO) - Total Assets
Based on the latest financial reports, Biosynex (ALBIO) holds total assets worth €149.44 Million EUR (≈ $174.71 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ALBIO operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Biosynex - Total Assets Trend (2006–2024)
This chart illustrates how Biosynex's total assets have evolved over time, based on quarterly financial data. See ALBIO net asset value for net asset value and shareholders' equity analysis.
Biosynex - Asset Composition Analysis
Current Asset Composition (December 2024)
Biosynex's total assets of €149.44 Million consist of 33.1% current assets and 66.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.4% |
| Accounts Receivable | €10.90 Million | 5.6% |
| Inventory | €32.66 Million | 16.8% |
| Property, Plant & Equipment | €14.85 Million | 7.6% |
| Intangible Assets | €48.88 Million | 25.1% |
| Goodwill | €64.13 Million | 32.9% |
Asset Composition Trend (2006–2024)
This chart illustrates how Biosynex's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biosynex market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biosynex's current assets represent 33.1% of total assets in 2024, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2024, up from 1.7% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 1.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 32.9% of total assets.
Biosynex Competitors by Total Assets
Key competitors of Biosynex based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Getein Biotech Inc
SHG:603387
|
China | CN¥3.70 Billion |
|
Ningbo David Medical Device Co Ltd
SHE:300314
|
China | CN¥1.45 Billion |
|
Vieworks Co. Ltd
KQ:100120
|
Korea | ₩351.89 Billion |
|
Somnomed Ltd
AU:SOM
|
Australia | AU$79.90 Million |
Biosynex - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.41 | 0.84 | 2.62 |
| Quick Ratio | 1.40 | 0.41 | 1.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €36.12 Million | €-13.44 Million | €23.32 Million |
Biosynex - Advanced Valuation Insights
This section examines the relationship between Biosynex's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -19.5% |
| Total Assets | €194.69 Million |
| Market Capitalization | $15.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biosynex's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biosynex's assets decreased by 19.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biosynex (2006–2024)
The table below shows the annual total assets of Biosynex from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €194.69 Million ≈ $227.61 Million |
-19.46% |
| 2023-12-31 | €241.73 Million ≈ $282.61 Million |
-7.02% |
| 2022-12-31 | €259.98 Million ≈ $303.94 Million |
-3.33% |
| 2021-12-31 | €268.94 Million ≈ $314.42 Million |
+113.32% |
| 2020-12-31 | €126.07 Million ≈ $147.39 Million |
+166.29% |
| 2019-12-31 | €47.34 Million ≈ $55.35 Million |
+19.98% |
| 2018-12-31 | €39.46 Million ≈ $46.14 Million |
-2.59% |
| 2017-12-31 | €40.51 Million ≈ $47.36 Million |
+2.54% |
| 2016-12-31 | €39.51 Million ≈ $46.19 Million |
+41.34% |
| 2015-12-31 | €27.95 Million ≈ $32.68 Million |
+311.38% |
| 2014-12-31 | €6.79 Million ≈ $7.94 Million |
-7.04% |
| 2013-12-31 | €7.31 Million ≈ $8.55 Million |
-17.38% |
| 2012-12-31 | €8.85 Million ≈ $10.34 Million |
+45.33% |
| 2011-12-31 | €6.09 Million ≈ $7.12 Million |
+470.28% |
| 2010-12-31 | €1.07 Million ≈ $1.25 Million |
+70.95% |
| 2009-12-31 | €624.41K ≈ $730.00K |
+8.16% |
| 2008-12-31 | €577.27K ≈ $674.89K |
+53.94% |
| 2007-12-31 | €375.00K ≈ $438.41K |
-10.93% |
| 2006-12-31 | €421.00K ≈ $492.19K |
-- |
About Biosynex
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hyg… Read more